Evidence explorer
Every claim we hold, and how far we can stand behind it.
142 claims across 39 products. 30% are confirmed against the source text by the evidence gate; 39% come from a class with no vendor interest. Everything below is browsable, filterable, and available as JSON.
What this corpus is made of
| Evidence class | Claims | Confirmed | What it can support |
|---|---|---|---|
| Peer-reviewed study | 19 | 5 | Independent review before publication. The only class that survives a sceptical committee unaided. |
| Regulatory filing | 4 | 0 | A statement made to a regulator, where being wrong has consequences. |
| Independent report | 32 | 9 | Analysis by someone with no stake in the sale. |
| Customer case | 4 | 3 | A real deployment, but selected and framed by someone with an interest. |
| Press release | 63 | 23 | The vendor's own announcement. Useful for dates and facts, not for outcomes. |
| Vendor page | 20 | 2 | Marketing copy. Establishes what is claimed, never that it is true. |
Showing 1 of 1 matching claims (142 in the full corpus) · 0% of this selection is confirmed · clear filters
Cluster-randomized controlled trial in J Med Libr Assoc (2019 Apr 1;107(2):151-162, doi 10.5195/jmla.2019.581) evaluated VisualDx as a clinical evidence technology for skin problems in primary care: 'Thirty-two PCPs and 433 patients participated', and time from index visit to skin problem resolution was similar in both groups (hazard ratio=0.92; 95% CI 0.70, 1.21; p=0.54).
Provenance
- Claim ID
- clm_fa1a96f540b206b3d969
- Version
- 1
- Workflow
- Clinical Evidence & Decision Support
- Dimension
- evidence strength
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6466492/